In 2014, Credit Suisse estimated that the U.S. government will provide over $1 billion in contracts to companies to develop medicine and vaccines for Ebola virus disease.[65] Congress passed a law in 2004, that funds a national stockpile of vaccines and medicine for possible outbreaks of disease.[65] A number of companies were expected to develop Ebola vaccines: GlaxoSmithKline, NewLink Genetics, Johnson & Johnson and Bavarian Nordic.[65] Another company, Emergent BioSolutions, was a contestant for manufacturing new doses of ZMapp,[citation needed] a drug for Ebola virus disease treatment originally developed by Mapp Biopharmaceutical.[66] Supplies of ZMapp ran out in August 2014.[67] In September 2014, the Biomedical Advanced Research and Development Authority (BARDA) entered into a multimillion-dollar contract with Mapp Biopharmaceutical to accelerate the development of ZMapp.[68] Additional contracts were signed in 2017.[69]